Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid

BioTechGrid

  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
Posted inBiotechnology

ACS Unifies Its Identity to Advance Science and Support Its People

August 5, 2026
Continue Reading
acs-unifies-its-identity-to-advance-science-and-support-its-people
Posted inBiotechnology

Study Finds Newborn Circumcision Does Not Increase Autism Risk

August 5, 2026
Continue Reading
study-finds-newborn-circumcision-does-not-increase-autism-risk
Posted inBiotechnology

Yao Earns Prestigious NSF CAREER Award

August 5, 2026
Continue Reading
yao-earns-prestigious-nsf-career-award
Posted inBiotechnology

New strategy shows promise against cancer drug resistance

August 4, 2026
Continue Reading
new-strategy-shows-promise-against-cancer-drug-resistance
Posted inBiotechnology

China study finds hospitals minimally affect antibiotic resistance in nearby waters

August 4, 2026
Continue Reading
china-study-finds-hospitals-minimally-affect-antibiotic-resistance-in-nearby-waters
Posted inBiotechnology

GLP-1 drugs tied to fewer fractures in adults with type 2 diabetes

August 4, 2026
Continue Reading
glp-1-drugs-tied-to-fewer-fractures-in-adults-with-type-2-diabetes
Most Popular Post
exploring-the-future-of-healthcare with-panos-karelis
Posted inArtificial intelligence

Exploring the Future of Healthcare with Panos Karelis

exploring-the-future-of-healthcare with-gordon-wishart,-check4cancer
Posted inArtificial intelligence

Exploring the Future of Healthcare with Gordon Wishart, Check4Cancer

exploring-the-future-of-healthcare with-noam-shomron,-tel-aviv-university
Posted inArtificial intelligence

Exploring the Future of Healthcare with Noam Shomron, Tel Aviv University

exploring-the-future-of-healthcare with-raul-villamarin-rodriguez,-woxsen-university
Posted inArtificial intelligence

Exploring the Future of Healthcare with Raul Villamarin Rodriguez, Woxsen University

galectin’s-mash-treatment-reduces-varices-but-fails-to-hit-statistical-significance-in-phase-3-trial
Posted inBiotechnology

Galectin’s MASH treatment reduces varices but fails to hit statistical significance in phase 3 trial

December 20, 2024
Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce enlarged veins for people…
Read More
clinical-research-company-javara-lays-off-employees-as-part-of-restructuring
Posted inResearch

Clinical research company Javara lays off employees as part of restructuring

December 20, 2024
Clinical research firm Javara has laid off staff as part of a restructuring, a spokesperson confirmed to Fierce Biotech in…
Read More
applied-therapeutics-ceo-steps-down-in-wake-of-fda-rejection,-warning-letter-and-investor-lawsuit
Posted inBiotechnology

Applied Therapeutics CEO steps down in wake of FDA rejection, warning letter and investor lawsuit

December 20, 2024
A turbulent month at Applied Therapeutics is being capped off with the departure of CEO and chair Shoshana Shendelman, Ph.D.,…
Read More
sanofi-scoops-up-china-rights-to-cytokinetics’-heart-disease-med-ahead-of-approval-decision
Posted inBiotechnology

Sanofi scoops up China rights to Cytokinetics’ heart disease med ahead of approval decision

December 20, 2024
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to…
Read More
apollomics,-after-giving-up-on-glycomimetics’-leukemia-therapy,-posts-drug’s-latest-phase-3-fail
Posted inBiotechnology

Apollomics, after giving up on GlycoMimetics’ leukemia therapy, posts drug’s latest phase 3 fail

December 20, 2024
The failure of a myeloid leukemia drug in a phase 3 trial in China isn’t a shock to Apollomics, which…
Read More
novo-nordisk-stock-crashes-after-cagrisema-misses-phase-3-weight-loss-goal
Posted inBiotechnology

Novo Nordisk stock crashes after CagriSema misses phase 3 weight-loss goal

December 20, 2024
A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss…
Read More
idorsia’s-sale-of-tryvio-falls-behind-schedule,-but-layoffs-remain-on-track
Posted inBiotechnology

Idorsia’s sale of Tryvio falls behind schedule, but layoffs remain on track

December 20, 2024
Idorsia’s plans to sell its hypertension drug Tryvio have faced a speedbump, even as the biotech ploughs ahead with around…
Read More
aadi-pulls-commercial-to-preclinical-pivot,-buying-adcs-and-selling-approved-drug-to-reboot-business
Posted inBiotechnology

Aadi pulls commercial-to-preclinical pivot, buying ADCs and selling approved drug to reboot business

December 20, 2024
Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and…
Read More
mechanism-for-cellular-rna’s-role-in-antiviral-immune-response-uncovered
Posted inGenetics

Mechanism for Cellular RNA’s Role in Antiviral Immune Response Uncovered

December 20, 2024
New research from scientists at the University of Washington (UW) School of Medicine and Duke University describes how cellular RNA…
Read More
ai-expedites-motor-neuron-analysis-and-screening-in-als-research
Posted inGenetics

AI Expedites Motor Neuron Analysis and Screening in ALS Research

December 20, 2024
Developing motor neurons from stem cells taken directly from amyotrophic lateral sclerosis (ALS) patients offers new hope for better understanding…
Read More

Posts pagination

Previous page 1 … 2,125 2,126 2,127 2,128 2,129 … 2,141 Next page
You May Have Missed
Posted inMedical Technology

Smith & Nephew cuts 2026 outlook as US knee implant sales slide

Posted inMedical Technology

KKR inks $5.7B deal to take medtech manufacturing giant Integer private

Posted inMedical Technology

Curium strikes up to $8B deal for radiopharma rival Lantheus

Posted inMedical Technology

Labcorp posts higher Q2 earnings on strength of diagnostics, lab services; adjusts full-year guidance

Privacy Policy    Terms

Scroll to Top